Subsense is developing a non-surgical brain-computer interface that delivers charged nanoparticles intranasally (like nasal spray) into the brain, then controls them via a magnetic coil headset to either stimulate neurons or read their activity. The company is currently in preclinical stage—testing on mice, validating core mechanisms—with commercial medical use years away at minimum. Ray Kurzweil has joined as a product and vision advisor. The source is clear on the mechanism (nasal delivery + magnetic control) and current stage (preclinical), but doesn't detail what specific neuron read/write fidelity they've achieved, whether the nanoparticles are biocompatible long-term, or what their actual timeline assumptions are. It's a real company with $27M funding positioning this as an alternative to Neuralink's surgical implant approach, though the "eventually consumer product" framing is purely aspirational at this stage.